Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs

June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A complete list of Janssen-sponsored abstracts scheduled for presentation during ASCO and EHA is available at the Janssen Oncology Virtual Newsroom. “Through a deliberate scientific focus on deep disease understanding, we continue to advance a diverse, differentiated portfolio and pipeline of targeted therapies and combination regimens in select cancers where unmet medical needs persist,” said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research &Development, LLC. “At this year’s ASCO, we look forward to presenting the latest research from our dedicated scientists on behalf of investigators, study centers and the patients participating in our programs, with a focus on improving the lives of patients diagnosed with cancer and driving toward the elimination of cancer in the future.” “At Jans...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

More News: Acetaminophen | Acute Leukemia | Alcoholism | Alimta | Allergy & Immunology | Alopecia | Amyloidosis | Anaphylactic Shock | Anemia | Arrhythmia | Atrial Fibrillation | Back Pain | Biotechnology | Bladder Cancer | Bleeding | Blood Transusion | Brain | Brain Cancers | Breast Cancer | Breast Carcinoma | Breastfed | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiac Arrhythmia | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemistry | Chemotherapy | Child Development | Children | China Health | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Obstructive Pulmonary | Chronic Pain | Clinical Trials | Constipation | Corticosteroid Therapy | Cough | Dermatitis | Dermatology | Dexamethasone | Diabetes | Drugs & Pharmacology | Emergency Medicine | Endocrinology | Epilepsy | Epithelial Cancer | European Medicines Agency (EMA) | Fundoscopy | Gastroenterology | Genetics | Hay Fever | Headache | Health Management | Heart | Heart Attack | Heart Disease | Heart Transplant | Hematology | Hemorrhagic Stroke | Hormones | Hypertension | Hypothyroidism | Immunotherapy | Infectious Diseases | Insomnia | Interstitial Lung Disease | Laboratory Medicine | Laryngeal Cancer | Learning | Legislation | Leukemia | Lortab | Lung Cancer | Lung Transplant | Lymphoma | Macroglobulinemia | Magnesium | Marketing | Melanoma | Migraine | Molecular Biology | Myeloma | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Neuroscience | Neurosurgery | Non-Small Cell Lung Cancer | Nonmelanoma Skin Cancer | Onycholysis | Opthalmology | Oral Cancer | Organic | Orthopaedics | Pain | Pain Management | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Politics | Potassium | Pregnancy | Pregnancy and Breast Cancer | Primary CNS Lymphoma | Profits and Losses | Prostate Cancer | Pulmonary Hypertension | Reflex Sympathetic Dystrophy | Reproduction Medicine | Respiratory Medicine | Revlimid | Science | Serous Carcinoma | Skin | Skin Cancer | Skin Graft | Sodium | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Thyroid | Thyroid Cancer | Toxicology | Transplant Surgery | Transplants | Universities & Medical Training | Vaccines | Velcade | Veterinary Vaccinations | Vitamin A | Waldenstrom's Macroglobulinemia | Warnings | Women